Stocks and Investing
Stocks and Investing
Mon, March 25, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, March 22, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, March 21, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Alethia Young Downgraded (BIIB) to Hold on, Mar 21st, 2019
Alethia Young of Cantor Fitzgerald, Downgraded "Biogen Inc." (BIIB) to Hold on, Mar 21st, 2019.
Alethia has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Alethia's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Adnan Butt of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $325 on, Friday, February 22nd, 2019
- Ian Somaiya of "BMO Capital" Initiated at Hold and Held Target at $322 on, Friday, February 22nd, 2019
- Thomas Shrader of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $346 on, Thursday, February 21st, 2019
This is the rating of the analyst that currently disagrees with Alethia
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $401 on, Wednesday, December 19th, 2018
Contributing Sources